Evidence map›Paper›PMID 39217794›Full record

ArticleBiomaterials2025

Alginate-based artificial antigen presenting cells expand functional CD8

Mary O Omotoso, Savannah E Est-Witte, Sydney R Shannon, Shuyi Li, Nina M Nair, Sarah Y Neshat, Si-Sim Kang, Stephany Y Tzeng, Jordan J Green, Jonathan P Schneck

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomaterials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Immunomodulatory Delivery Materials for Tissue Repair.Advanced healthcare materials · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Mary O OmotosoDepartment of Biomedical Engineering, School of Medicine, USA; Institute for Cell Engineering, School of Medicine, USA; Department of Pathology, School of Medicine, USA.
Savannah E Est-WitteDepartment of Biomedical Engineering, School of Medicine, USA; Translational Tissue Engineering Center, USA; Institute for NanoBioTechnology, USA.
Sydney R ShannonDepartment of Biomedical Engineering, School of Medicine, USA; Department of Pathology, School of Medicine, USA; Translational Tissue Engineering Center, USA; Institute for NanoBioTechnology, USA.
Shuyi LiDepartment of Pathology, School of Medicine, USA; Institute for NanoBioTechnology, USA.
Nina M NairDepartment of Biomedical Engineering, Whiting School of Engineering, USA.
Sarah Y NeshatDepartment of Biomedical Engineering, School of Medicine, USA; Translational Tissue Engineering Center, USA; Institute for NanoBioTechnology, USA.
Si-Sim KangDepartment of Pathology, School of Medicine, USA.
Stephany Y TzengTranslational Tissue Engineering Center, USA; Department of Biomedical Engineering, Whiting School of Engineering, USA; Johns Hopkins Translational ImmunoEngineering Center, USA.
Jordan J GreenDepartment of Biomedical Engineering, School of Medicine, USA; Translational Tissue Engineering Center, USA; Institute for NanoBioTechnology, USA; Johns Hopkins Translational ImmunoEngineering Center, USA. Electronic address: green@jhu.edu.
Jonathan P SchneckDepartment of Biomedical Engineering, School of Medicine, USA; Institute for Cell Engineering, School of Medicine, USA; Department of Pathology, School of Medicine, USA; Johns Hopkins Translational ImmunoEngineering Center, USA; Department of Medicine, School of Medicine, Johns Hopkins University, Baltimore, MD, USA. Electronic address: jschnec1@jhmi.edu.

Funding

TR&D Project 3P41EB028239 · NIBIB · JOHNS HOPKINS UNIVERSITY · PI Jamie Berta Spangler · 2019 to 2026
$11.5M
A PLATFORM TECHNOLOGY TO GENETICALLY REPROGRAM CANCER CELLS FOR ENHANCED IMMUNOTHERAPYR37CA246699 · NCI · JOHNS HOPKINS UNIVERSITY · PI TZENG, STEPHANY YI · 2020 to 2025
$2.6M
Biomimetic Matrix for Ex Vivo and In Vivo Activation of T CellsR01EB029341 · NIBIB · JOHNS HOPKINS UNIVERSITY · PI MAO, HAI-QUAN, SCHNECK, JONATHAN P · 2020 to 2023
$1.9M
Gene Delivery Nanoparticles to Treat GlioblastomaR01CA228133 · NCI · JOHNS HOPKINS UNIVERSITY · PI GREEN, JORDAN · 2019 to 2023
$1.9M
A high-throughput nanoparticle assay to characterize cancer neoepitope-specific T cellsR33CA229042 · NCI · JOHNS HOPKINS UNIVERSITY · PI SCHNECK, JONATHAN P · 2019 to 2021
$1.4M
Tri-Signal Artificial Antigen Presenting Cells for Cancer ImmunotherapyF31CA284859 · NCI · JOHNS HOPKINS UNIVERSITY · PI SHANNON, SYDNEY ROSE · 2023 to 2025
$129k
NCI NIH HHS F31 CA284859NCI NIH HHS R01 CA228133NCI NIH HHS R33 CA229042NCI NIH HHS R37 CA246699NIBIB NIH HHS P41 EB028239NIBIB NIH HHS R01 EB029341
6 · The paper itself

Abstract

The development of artificial Antigen Presenting Cells (aAPCs) has led to improvements in adoptive T cell therapy (ACT), an immunotherapy, for cancer treatment. aAPCs help to streamline the consistent production and expansion of T cells, thus reducing the time and costs associated with ACT. However, several issues still exist with ACT, such as insufficient T cell potency, which diminishes the translational potential for ACT. While aAPCs have been used primarily to increase production efficiency of T cells for ACT, the intrinsic properties of a biomaterial-based aAPC may affect T cell phenotype and function. In CD8

Indexed as

AlginatesAntigen-Presenting CellsCD8-Positive T-LymphocytesImmunologic MemoryImmunotherapy, AdoptiveAnimalsCell ProliferationHumansMiceMice, Inbred C57BLReactive Oxygen SpeciesAlginatesReactive Oxygen SpeciesAdoptive T cell therapyAlginateCD8(+) T cellMemory T cellPersistence

Identifiers

PMID39217794
PMCPMC11423771

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.